Idexx Laboratories Inc (NASDAQ:IDXX) Stock Sentiment Increases

September 23, 2017 - By Marguerite Chambers

 Idexx Laboratories Inc (NASDAQ:IDXX) Stock Sentiment  Increases

Sentiment for Idexx Laboratories Inc (NASDAQ:IDXX)

Idexx Laboratories Inc (NASDAQ:IDXX) institutional sentiment increased to 1.19 in Q2 2017. Its up 0.25, from 0.94 in 2017Q1. The ratio has increased, as 253 funds started new and increased equity positions, while 212 sold and reduced stock positions in Idexx Laboratories Inc. The funds in our partner’s database now possess: 76.34 million shares, down from 76.98 million shares in 2017Q1. Also, the number of funds holding Idexx Laboratories Inc in their top 10 equity positions decreased from 19 to 15 for a decrease of 4. Sold All: 28 Reduced: 184 Increased: 167 New Position: 86.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company has market cap of $13.75 billion. The Firm also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. It has a 54.05 P/E ratio. The Company’s divisions include diagnostic and information technology services and products for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic services and products for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements.

The stock increased 1.12% or $1.74 on September 22, reaching $157.5. About 362,117 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since September 23, 2016 and is uptrending. It has outperformed by 66.60% the S&P500.

Wall Street await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to release earnings on November, 7. Analysts forecast earnings per share of $0.75, up exactly $0.13 or 20.97 % from 2014’s $0.62 EPS. The expected IDXX’s profit could reach $65.48M giving the stock 52.50 P/E in the case that $0.75 earnings per share is reported. After posting $0.95 EPS for the previous quarter, IDEXX Laboratories, Inc.’s analysts now forecast -21.05 % negative EPS growth.

Capital Counsel Llc Ny holds 10.82% of its portfolio in IDEXX Laboratories, Inc. for 735,838 shares. Fundsmith Llp owns 4.45 million shares or 7.53% of their US portfolio. Moreover, American Capital Management Inc has 5.36% invested in the company for 519,048 shares. The New York-based Bamco Inc Ny has invested 3.9% in the stock. Tirschwell & Loewy Inc, a New York-based fund reported 154,000 shares.#img1#

Since January 1, 0001, it had 0 buys, and 5 sales for $10.08 million activity.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage

Ratings analysis reveals 56% of IDEXX Laboratories’s analysts are positive. Out of 9 Wall Street analysts rating IDEXX Laboratories, 5 give it “Buy”, 2 “Sell” rating, while 2 recommend “Hold”. The lowest target is $69.50 while the high is $185.0. The stock’s average target of $119.08 is -24.39% below today’s ($157.5) share price. IDXX was included in 20 notes of analysts from July 24, 2015. The firm has “Market Perform” rating by Raymond James given on Friday, August 28. The firm has “Buy” rating given on Tuesday, June 13 by Canaccord Genuity. The firm earned “Neutral” rating on Thursday, September 29 by Bank of America. On Wednesday, April 13 the stock rating was maintained by Credit Suisse with “Outperform”. The firm has “Buy” rating given on Thursday, October 29 by Stifel Nicolaus. The firm has “Hold” rating given on Friday, July 24 by Feltl & Co. The company was upgraded on Wednesday, August 23 by Bank of America. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Outperform” rating by Credit Suisse on Thursday, February 4. CL King initiated IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Friday, April 1 with “Neutral” rating. The firm earned “Buy” rating on Monday, August 21 by Stifel Nicolaus.

More recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Benzinga.com which released: “IDEXX Labs Is ‘Top Dog'” on August 24, 2017. Also Finance.Yahoo.com published the news titled: “IDEXX Laboratories (IDXX), Great Growth Pick: Here’s Why” on August 25, 2017. Nasdaq.com‘s news article titled: “Here’s Why You Should Invest in IDEXX Laboratories (IDXX) Now” with publication date: September 21, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.